| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 2,642 | 2,507 | +5.4% |
| EBITDA | 259 | 192 | +34.5% |
| EBITDA margin | 9.8% | 7.7% | +2.1 pts |
| Profit before tax | 144 | 75.1 | +92.0% |
| Net profit | 103 | 55.0 | +88.0% |
| EPS | ₹12.30 | ₹6.00 | +105.0% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 7,960 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 1,256 | 1,256 | 1,433 | 47.2 | 20.4 | ||
| 404 | 404 | 598 | 0.0 | 0.0 | ||
| 2,119 | 2,119 | 2,085 | 441 | 817 | ||
| 9,227 | — | — | — | — | ||
| 9,922 | 9,787 | 3,346 | 2,539 | 2,302 | ||
| — | +192.5% | +31.8% | +10.3% | — | ||
| 656 | 590 | 381 | 316 | 211 | ||
| 6.6% | 6.0% | 11.4% | 12.5% | 9.2% | ||
| 315 | 243 | 215 | 175 | 96.4 | ||
| 89.2 | 40.8 | 60.2 | 357 | 44.8 | ||
| 0.9% | 0.4% | 1.8% | 14.1% | 2.0% | ||
| ₹9.22 | ₹2.84 | ₹7.10 | ₹45.53 | ₹5.70 | ||
| — | −60.0% | −84.4% | +698.4% | — | ||
| — | 344 | 37.0 | 193 | 287 | ||
| — | −270 | −94.6 | −78.5 | −192 | ||
| 73.6 | 73.6 | −57.5 | 115 | 94.6 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 7,959.9 | |
| - Cash, Equiv & ST Investments | 20.4 | 47.2 | 1,432.5 | 1,255.9 | 1,255.9 | |
| + Minority Interest | 0.0 | 0.0 | 598.2 | 403.8 | 403.8 | |
| + Total Debt | 817.5 | 440.9 | 2,084.7 | 2,119.0 | 2,119.0 | |
| Enterprise Value | — | — | — | — | 9,226.8 | |
| Revenue | 2,301.7 | 2,538.8 | 3,345.6 | 9,787.2 | 9,922.4 | |
| Growth %, YoY | — | +10.3 | +31.8 | +192.5 | — | |
| EBITDA | 210.6 | 316.4 | 381.0 | 589.9 | 656.3 | |
| Margin % | 9.15 | 12.46 | 11.39 | 6.03 | 6.61 | |
| EBIT | 96.4 | 175.2 | 214.8 | 242.7 | 315.0 | |
| Net Income | 44.8 | 357.4 | 60.2 | 40.8 | 89.2 | |
| Margin % | 1.95 | 14.08 | 1.80 | 0.42 | 0.90 | |
| EPS, Adj (current shares) | 5.70 | 45.53 | 7.10 | 2.84 | 9.22 | |
| Growth %, YoY | — | +698.4 | -84.4 | -60.0 | — | |
| Cash from Operations | 287.0 | 193.5 | 37.0 | 344.0 | — | |
| Capital Expenditures | -192.4 | -78.5 | -94.6 | -270.4 | — | |
| Free Cash Flow | 94.6 | 115.0 | -57.5 | 73.6 | 73.6 | |
Prices at the previous close · figures from the company's filings with NSE
Sudarshan Chemical Industries (NSE: SUDARSCHEM) had a market capitalisation of ₹8,061 crore at the previous close (₹1,014.00 a share), a PE ratio of 111.3 on the last four quarters' profit and a price-to-book ratio of 2.34. In FY26 its consolidated net profit attributable to shareholders was ₹22.3 crore on revenue of ₹9,787 crore; in Q1 FY27 (April–June 2026) it was ₹97.3 crore, up 106.1% year on year. Its debt-to-equity ratio was 0.55 on 31 March 2026. Promoters held 9.32% of the shares on 30 September 2026.
Sudarshan Chemical Industries' PE ratio is 111.3 at the previous close (₹1,014.00 a share): a market capitalisation of ₹8,061 crore divided by consolidated net profit attributable to shareholders of ₹72.4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹22.3 crore) it is 361.5. These four quarters include net exceptional items of −₹29.7 crore (one-off charges reported separately), so the ratio on recurring profit would differ.
Sudarshan Chemical Industries' price-to-book (PB) ratio is 2.34 at the previous close: a market capitalisation of ₹8,061 crore divided by shareholders' equity (book value) of ₹3,450 crore on 31 March 2026. That is a book value of ₹433.99 per share against a share price of ₹1,014.00.
In FY26, Sudarshan Chemical Industries' return on equity (ROE) was 0.7% and its return on capital employed (ROCE) was 3.6%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 2.4% and ROCE 5.2%.
Sudarshan Chemical Industries' market capitalisation was ₹8,061 crore at the previous close: 7.95 crore shares at ₹1,014.00 each.
No. Sudarshan Chemical Industries had borrowings of ₹2,119 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.55. Its cash and current investments were ₹1,398 crore, so its net debt was ₹721 crore.
Sudarshan Chemical Industries' debt-to-equity ratio was 0.55 on 31 March 2026: borrowings of ₹2,119 crore against total equity of ₹3,854 crore. A year earlier, on 31 March 2025, it was 0.52.
Sudarshan Chemical Industries' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,450 crore on 31 March 2026, up 0.3% from ₹3,440 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹8,061 crore at the previous close.
Sudarshan Chemical Industries' book value per share was ₹433.99 on 31 March 2026: shareholders' equity of ₹3,450 crore divided by the 7.95 crore shares in issue, down 0.9% from ₹437.80 a year earlier. The share price at the previous close was ₹1,014.00.
Sudarshan Chemical Industries' dividend yield is 0.49% at the previous close: dividends of ₹5 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,014.00. They were ₹5 on 11 August 2026.
Sudarshan Chemical Industries' basic earnings per share (EPS) were ₹2.80 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹9.10.
In 2026, Sudarshan Chemical Industries has declared one dividend: ₹5 with record date 11 August 2026.
Sudarshan Chemical Industries has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
Promoters held 9.32% of Sudarshan Chemical Industries on 30 September 2026, up 1.13 percentage points from 8.19% the previous quarter and up 1.13 percentage points from 8.19% a year earlier, according to the shareholding pattern filed with NSE.
In FY26, Sudarshan Chemical Industries generated ₹344 crore of cash from operations and spent ₹270 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹73.6 crore. In FY25 it was −₹57.5 crore.
Sudarshan Chemical Industries' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit attributable to shareholders ₹97.3 crore, up 106.1% from ₹47.2 crore in Q1 FY26; revenue from operations ₹2,642 crore, up 5.4% year on year.
On 30 September 2026, Sudarshan Chemical Industries' shares were held by promoters 9.32%, foreign portfolio investors (FII/FPI) 8.84%, domestic institutions (DII) 27.90% (including mutual funds at 25.44%) and retail and other non-institutional investors 53.94%. Over the year, FII holding was up 0.30 percentage points from 8.54% and DII holding was up 3.71 percentage points from 24.19%.
In FY26 (April 2025–March 2026), Sudarshan Chemical Industries' consolidated net profit attributable to shareholders was ₹22.3 crore, down 60.0% from ₹55.8 crore in FY25, on revenue from operations of ₹9,787 crore (up 192.5%). Over three years, from FY23, net profit was down 50.2%.
On FY26 consolidated figures, against Sudeep Pharma, Styrenix Performance Materials and Sharda Cropchem: Sudarshan Chemical Industries' operating margin of 2.5% is the lowest of the four (Sudeep Pharma 32.2%, Styrenix Performance Materials 6.7%, Sharda Cropchem 14.3%; peer average 17.7%); its return on equity of 0.7% is the lowest of the four (Sudeep Pharma 19.6%, Styrenix Performance Materials 14.4%, Sharda Cropchem 24.2%; peer average 19.4%).
In FY26, Sudarshan Chemical Industries earned net profit attributable to shareholders of ₹22.3 crore on revenue of ₹9,787 crore, against ₹173 crore on ₹642 crore for Sudeep Pharma. Sudarshan Chemical Industries' operating margin was 2.5% (Sudeep Pharma 32.2%) and its return on equity 0.7% (Sudeep Pharma 19.6%).
From Sudarshan Chemical Industries' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.